VIP-236 is under clinical development by Vincerx Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VIP-236’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VIP-236 overview
VIP-236 is under development for the treatment of advanced and metastatic solid tumors like small cell lung cancer (SCLC), non-small cell lung cancer, adeno cystic carcinoma, renal cell carcinoma(RCC), ovarian cancer, colorectal cancer (CRC), triple negative breast cancer(TNBC) and ovarian cancer, breast cancer, sarcomas, endometrial cancer, gastric cancer. It is administered by intravenous route. The drug candidate is a small molecule drug conjugate (SMDC) consisting of an alpha v beta 3 integrin binder and a linker that is cleavable by neutrophil elastase. The payload is a modified camptothecin derivative designed for extracellular release. It is being developed based on VersAptx Platform.
Vincerx Pharma overview
Vincera Pharma Inc (Vincera) is a clinical-stage biopharmaceutical company. It discovers and develops therapies for the treatment of cancer. The company’s pipeline product candidates include enitociclib, a CDK9 Inhibitor for MYC-rearranged DLBCL, and Non-GCB DLBCL and Peripheral T-cell Lymphoma. Vincera other pipeline includes VIP236 for the treatment of multiple solid tumors; VIP943, a KSP inhibitor against leukemia, VIP924, an antibody-drug conjugate to treat B-cell malignancies. The company is evaluating therapeutic programs for solid and hematologic tumors. It also utilizes its proprietary bio conjugate platform to develop therapies in the areas of oncology. Vincera is headquartered in Santa Clara, California, the US.
For a complete picture of VIP-236’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
